Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Monlunabant

Stage Phase 2Stale

Sponsor Inversago Pharma Inc.

Route oral

Class CB1

Mechanism cannabinoid receptor 1 inverse agonist

Sources

registry, as of 2025-03-27Stale

https://clinicaltrials.gov/study/NCT05282446

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome. Overall status COMPLETED. Phases PHASE1. Lead sponsor Inversago Pharma Inc.. Enrollment 37. Conditions Metabolic Syndrome. INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic syndrome over 28 days.

ClinicalTrials.gov NCT05282446 protocol and results modules

registry, as of 2025-11-18Stale

https://clinicaltrials.gov/study/NCT06542536

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 73. Conditions Obesity. The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body. Oral monlunabant is a new medicine which cannot be prescr

ClinicalTrials.gov NCT06542536 protocol and results modules

registry, as of 2025-06-05Stale

https://clinicaltrials.gov/study/NCT05891834

Study of INV-202 in Patients With Obesity and Metabolic Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Inversago Pharma Inc.. Enrollment 243. Conditions Obesity; Metabolic Syndrome. The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.

ClinicalTrials.gov NCT05891834 protocol and results modules

publication, as of 2025-10-16Stale

https://pubmed.ncbi.nlm.nih.gov/41038215/

metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability. We aimed to evaluate the efficacy and safety of monlunabant in individuals with obesity and metabolic syndrome. This

PMID 41038215

Studies

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Registry NCT05282446

Phase Phase 1

Status Completed

Enrollment 37

Start 2022-03-01

Primary completion 2022-09-11

Study completion 2022-10-01

INV-202

Regimen once daily

Comparator placebo

Population Metabolic Syndrome

Placebo

Regimen once daily

Population Metabolic Syndrome

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

Registry NCT06542536

Phase Phase 1

Status Completed

Enrollment 73

Start 2024-08-09

Primary completion 2024-10-25

Study completion 2024-10-25

Monlunabant dose 1

Comparator placebo

Population Obesity

Monlunabant dose 2

Comparator placebo

Population Obesity

Monlunabant dose 3

Comparator placebo

Population Obesity

Placebo (monlunabant)

Population Obesity

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Registry NCT05891834

Phase Phase 2

Status Completed

Enrollment 243

Start 2023-09-08

Primary completion 2024-06-13

Study completion 2025-02-14

Low dose

Regimen once daily

Comparator placebo

Population Obesity; Metabolic Syndrome

High dose

Regimen once daily

Comparator placebo

Population Obesity; Metabolic Syndrome

Placebo

Regimen once daily

Population Obesity; Metabolic Syndrome

Middle Dose

Regimen once daily

Comparator placebo

Population Obesity; Metabolic Syndrome